Measurement performance assessment for the ITER CXRS Edge diagnostic system.

Measurement performance assessment has been carried out for the latest design of the ITER Charge Exchange Recombination Spectroscopy (CXRS) Edge diagnostic system. Several plasma scenarios, covering all expected baseline operation regimes for ITER, were used. Various impurity (He, Be, C, and Ne) concentrations for the system whole spatial range (0.

Charge exchange recombination spectroscopy on the T-10 tokamak.

The charge exchange recombination spectroscopy (CXRS) diagnostics on the T-10 tokamak is described. The system is based on a diagnostic neutral beam and includes three high etendue spectrometers designed for the ITER edge CXRS system. A combined two-channel spectrometer is developed for simultaneous measurements of two beam-induced spectral lines using the same lines of sight.

Clinical characteristics and outcome of familial nonmedullary thyroid cancer: a retrospective controlled study.

Background: Familial nonmedullary thyroid cancer (FNMTC) is a disease defined by clustering of thyroid cancers of follicular cell origin, and it is estimated to account for 5% of all thyroid cancers. Several studies found FNMTC to be more aggressive than sporadic disease, whereas others found them to have a similar course and outcome. The purpose of this study was to determine whether FNMTC is more aggressive than sporadic thyroid cancer.

Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma.

Background: Exogenous subclinical hyperthyroidism, caused by long-term thyrotropin (TSH)-suppressive treatment with levothyroxine (LT(4)), is associated with several cardiovascular abnormalities. In order to assess the effect of long-term thyroid hormone-suppressive therapy on the blood vessels and myocardium, we determined the arterial elasticity, using the pulse wave contour analysis.

Methods And Results: Twenty-six athyreotic patients receiving TSH-suppressive LT(4) therapy for periods ranging from 3 to 21 years at a mean daily dose of 2.